The purpose of this study is to determine if home blood pressure monitors can help decrease blood pressure in patients with diabetes at a low income clinic.

Start Date01 Dec 2011

Sponsor / Collaborator

Exempla Saint Joseph Hospital

100 Clinical Results associated with SCL Health-Front Range, Inc.

0 Patents (Medical) associated with SCL Health-Front Range, Inc.

Literatures (Medical) associated with SCL Health-Front Range, Inc.

01 Jul 2022·Annals of Surgical OncologyQ2 · MEDICINE

Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

Q2 · MEDICINE

Article

Author: Richards, Paul D ; Pellicane, James V ; Yoder, Erin B ; Ashikari, Andrew Y ; Dul, Carrie L ; Barone, Julie L ; Kelemen, Pond ; Nash, Charles H ; Budway, Raye ; Corcoran, Kate ; Beitsch, Peter D ; Menicucci, Andrea R ; Finn, Christine ; Audeh, William ; Baron, Paul L ; Cowan, Ken ; Dupree, Beth ; Wang, Shiyu ; Gittleman, Mark ; Rahman, Rakhshanda Layeequr ; Murray, Mary K ; Whitworth, Pat ; Rock, David T ; Lee, Laura A ; Dooley, William C ; Blumencranz, Lisa E ; Lesnikoski, Beth-Ann

AbstractBackgroundThe Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR) in breast cancer patients. We report 5-year follow-up results in addition to an exploratory analysis by age and menopausal status. MethodsThe observational, prospective NBRST (NCT01479101) included 954 early-stage breast cancer patients aged 18–90 years who received neoadjuvant chemotherapy and had clinical and genomic data available. Chemosensitivity and 5-year distant metastasis-free survival (DMFS) and overall survival (OS) were assessed. In a post hoc subanalysis, results were stratified by age (≤ 50 vs. > 50 years) and menopausal status in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) tumors.ResultsMammaPrint and BluePrint further classified 23% of tumors to a different subtype compared with immunohistochemistry, with more precise correspondence to pCR rates. Five-year DMFS and OS were highest in MammaPrint Low Risk, Luminal A-type and HER2-type tumors, and lowest in MammaPrint High Risk, Luminal B-type and Basal-type tumors. There was no significant difference in chemosensitivity between younger and older patients with Low-Risk (2.2% vs. 3.8%; p = 0.64) or High-Risk tumors (14.5% vs. 11.5%; p = 0.42), or within each BluePrint subtype; this was similar when stratifying by menopausal status. The 5-year outcomes were comparable by age or menopausal status for each molecular subtype. ConclusionIntrinsic preoperative chemosensitivity and long-term outcomes were precisely determined by BluePrint and MammaPrint regardless of patient age, supporting the utility of these assays to inform treatment and surgical decisions in early-stage breast cancer.

01 Jul 2022·Annals of Surgical Oncology

ASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

Article

Author: Yoder, Erin B ; Richards, Paul D ; Blumencranz, Lisa E. ; Rock, David T. ; Pellicane, James V ; Dooley, William C. ; Ashikari, Andrew Y ; Kelemen, Pond ; Dul, Carrie L. ; Corcoran, Kate ; Beitsch, Peter D ; Lee, Laura A. ; Menicucci, Andrea R ; Finn, Christine ; Audeh, William ; Richards, Paul D. ; Murray, Mary K. ; Gittleman, Mark ; Cowan, Ken H ; Yoder, Erin B. ; Menicucci, Andrea R. ; Barone, Julie L. ; Whitworth, Pat ; Rock, David T ; Lee, Laura A ; Blumencranz, Lisa E ; Ashikari, Andrew Y. ; Dul, Carrie L ; Barone, Julie L ; Beitsch, Peter D. ; Pellicane, James V. ; Nash, Charles H ; Budway, Raye ; Nash, Charles H. ; Baron, Paul L. ; Baron, Paul L ; Dupree, Beth ; Wang, Shiyu ; Murray, Mary K ; Dooley, William C ; Cowan, Ken H. ; Layeequr Rahman, Rakhshanda ; Lesnikoski, Beth-Ann

01 May 2022·JCO Precision OncologyQ4 · MEDICINE

Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

Q4 · MEDICINE

Article

Author: Gittleman, Mark A. ; Rahman, Rakhshanda Layeequr ; Dupree, Beth B. ; Baron, Paul L. ; Budway, Raye J. ; Rock, David T. ; Whitworth, Pat W. ; Yoder, Erin B. ; Corcoran, Kate ; Wang, Shiyu ; Lesnikoski, Beth-Ann ; Ashikari, Andrew Y. ; Dooley, William C. ; Dul, Carrie L. ; Murray, Mary K. ; Beitsch, Peter D. ; Pellicane, James V. ; Kelemen, Pond R. ; Audeh, William ; Cowan, Kenneth H. ; Menicucci, Andrea R. ; Lee, Laura A. ; Barone, Julie L. ; Blumencranz, Lisa E. ; Finn, Christine

PURPOSE The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Basal-Type. We report the association of 80-GS reclassification with neoadjuvant treatment response and 5-year outcome in patients with breast cancer. METHODS Neoadjuvant Breast Registry Symphony Trial (NBRST; NCT01479101 ) is an observational, prospective study that included 1,069 patients with early-stage breast cancer age 18-90 years who received neoadjuvant therapy. Pathologic complete response (pCR) and 5-year distant metastasis-free survival (DMFS) and overall survival (OS) were assessed in 477 patients with IHC-defined ER+, HER2– tumors and in a reference group of 229 patients with IHC-defined triple-negative breast cancer (TNBC). RESULTS 80-GS reclassified 15% of ER+, HER2– tumors (n = 73) as Basal-Type (ER+/Basal), which had similar pCR compared with TNBC/Basal tumors (34% v 38%; P = .52), and significantly higher pCR than ER+/Luminal A (2%; P < .001) and ER+/Luminal B (6%; P < .001) tumors. The 5-year DMFS (%, [95% CI]) was significantly lower for patients with ER+/Basal tumors (66% [52.6 to 77.3]), compared with those with ER+/Luminal A tumors (92.3% [85.2 to 96.1]) and ER+/Luminal B tumors (73.5% [44.5 to 79.3]). Importantly, patients with ER+/Basal or TNBC/Basal tumors that had a pCR exhibited significantly improved DMFS and OS compared with those with residual disease. By contrast, patients with ER+/Luminal B tumors had comparable 5-year DMFS and OS whether or not they achieved pCR. CONCLUSION Significant differences in chemosensitivity and 5-year outcome suggest patients with ER+/Basal molecular subtype may benefit from neoadjuvant regimens optimized for patients with TNBC/Basal tumors compared with patients with ER+/Luminal subtype. These data highlight the importance of identifying this subset of patients to improve treatment planning and long-term survival.

100 Deals associated with SCL Health-Front Range, Inc.

100 Translational Medicine associated with SCL Health-Front Range, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 31 May 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SCL Health-Front Range, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 31 May 2026

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing